We present the preparation and characterization of viscoelastic formulations of hyaluronic acid functionalized with polymerizable methacrylate groups. We explored three different processing strategies for controlling microstructure and interchain interactions: lightly cross-linked near-gels, emulsion-cross-linked microspheres, and an elastic microgel formed through centrifuging the microspheres. The component structure and rheological properties of these formulations were compared to those of high molecular weight hyaluronic acid solutions, which displayed classical behavior of high molecular weight polymer solutions reported by other investigators. We demonstrate that these processing strategies allow the tuning of solution properties from strongly viscoelastic behavior, observed in lightly cross-linked near-gels and concentrated microsphere solutions to elastic behavior in elastic microgels, behaving like pseudoplastic liquids having a well-defined yield stress above which viscous behavior was observed. In the centrifuged microspheres, the hyaluronic acid degree of methacrylation was inversely proportional to the gel elasticity, and a mechanism based on failure due to microsphere brittleness is proposed to explain this behavior. These results suggest that processing methacrylated hyaluronic acid can lead to a diversity of solution properties, providing methods for delivering this biologically active polymer in a broad range of applications.

We report a thermoresponsive chemical modification strategy of hyaluronic acid (HA) for coating onto a broad range of biomaterials without relying on chemical functionalization of the surface. Poly(di(ethylene glycol) methyl ether methacrylate) (PMEO2MA), a polymer with a lower critical solution temperature of 26 °C in water, was grafted onto HA to allow facile formation of biopolymer coatings. While the mechanism for film formation appears to involve a complex combination of homogeneous nucleation followed by heterogeneous film growth, we demonstrate that it resulted in hydrophilic coatings that significantly reduce protein adsorption despite the high fraction of hydrophobic (PMEO2MA). Structural characterization was performed using atomic force microscopy (AFM), which showed the formation of a dense, continuous coating based on 200 nm domains that were stable in protein solutions for at least 15 days. The coatings had a water contact angle of 16°, suggesting the formation of hydrophilic but not fully wetting films. Quartz crystal microbalance with dissipation monitoring (QCM-D) as well as biolayer interferometry (BLI) techniques were used to measure adsorption of bovine serum albumin (BSA), fibrinogen (Fbg), and human immunoglobulin (IgG), with results indicating that HA-PMEO2MA-coated surfaces effectively inhibited adsorption of all three serum proteins. These results are consistent with previous studies demonstrating that this degree of hydrophilicity is sufficient to generate an effectively nonfouling surface and suggest that segregation during the solubility transition resulted in a surface that presented the hydrophilic HA component of the hybrid biopolymer. We conclude that PMEO2MA-grafted HA is a versatile platform for the passivation of hydrophobic biomaterial surfaces without need for substrate functionalization.

Burns, chronic wounds, osteoarthritis, and uveitis are examples of conditions characterized by local, intense inflammatory responses that can impede healing or even further tissue degradation. The most powerful anti-inflammatory drugs available are often administered systemically, but these carry significant side effects and are not compatible for patients that have underlying complications associated with their condition. Conjugation of monoclonal antibodies that neutralize pro-inflammatory cytokines to high molecular weight hydrophilic polymers has been shown to be an effective strategy for local control of inflammation. Lead formulations are based on antibody inhibitors of tumor necrosis factor-α conjugated to hyaluronic acid having molecular weight greater than 1 MDa. This review will discuss fundamental aspects of medical conditions that could be treated with these conjugates and design principles for preparing these cytokine-neutralizing polymer conjugates. Results demonstrating that infliximab, an approved inhibitor of tumor necrosis factor-α, can be incorporated into the conjugates using a broad range of water-soluble polymers are also presented, along with a prospectus for clinical translation.